Quotient Ltd. (QTNT) Lowered to Sell at Zacks Investment Research
Quotient Ltd. (NASDAQ:QTNT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
Quotient (NASDAQ:QTNT) opened at 7.595 on Wednesday. Quotient has a one year low of $5.67 and a one year high of $17.44. The company’s market capitalization is $109.19 million. The stock’s 50 day moving average price is $7.32 and its 200-day moving average price is $8.27.
In related news, insider D J. Paul E. Cowan purchased 45,455 shares of the business’s stock in a transaction dated Wednesday, August 3rd. The shares were acquired at an average cost of $5.50 per share, for a total transaction of $250,002.50. Following the acquisition, the insider now owns 26,666 shares of the company’s stock, valued at approximately $146,663. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director L John Wilkerson purchased 180,000 shares of the business’s stock in a transaction dated Wednesday, August 3rd. The stock was bought at an average price of $5.50 per share, for a total transaction of $990,000.00. The disclosure for this purchase can be found here. 40.50% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in QTNT. BlackRock Investment Management LLC increased its position in shares of Quotient by 2.5% in the second quarter. BlackRock Investment Management LLC now owns 86,418 shares of the company’s stock worth $670,000 after buying an additional 2,075 shares in the last quarter. BlackRock Group LTD increased its position in shares of Quotient by 2.4% in the second quarter. BlackRock Group LTD now owns 265,958 shares of the company’s stock worth $2,061,000 after buying an additional 6,167 shares in the last quarter. Geode Capital Management LLC bought a new position in shares of Quotient during the first quarter worth about $105,000. First New York Securities LLC NY bought a new position in shares of Quotient during the second quarter worth about $140,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Quotient during the first quarter worth about $172,000. Institutional investors and hedge funds own 41.50% of the company’s stock.
Quotient Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Stock Ratings for Quotient Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Ltd. and related stocks with our FREE daily email newsletter.